CCL21 and cancer: In an orthotopic PDAC animal model known to develop cancer-associated pain, administration of CXCL10- or CCL21-neutralizing antibodies significantly reduced the extent of nerve fiber hypertrophy and, consequently, the development of cancer-associated pain.